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Thermodynamically coupled biosensors for
detecting neutralizing antibodies against
SARS-CoV-2 variants
Jason Z. Zhang 1,2,14 ✉, Hsien-Wei Yeh 1,2,14, Alexandra C. Walls 1, Basile I. M. Wicky 1,2,
Kaitlin R. Sprouse 1, Laura A. VanBlargan 3, Rebecca Treger4, Alfredo Quijano-Rubio 2,5,
Minh N. Pham1,2, John C. Kraft 1,2, Ian C. Haydon 2, Wei Yang1,2, Michelle DeWitt2, John E. Bowen1,
Cameron M. Chow 2, Lauren Carter2, Rashmi Ravichandran2, Mark H. Wener 4, Lance Stewart 2,
David Veesler 1,6, Michael S. Diamond 3,7,8,9, Alexander L. Greninger4,10, David M. Koelle4,10,11,12,13 and
David Baker 1,2,6 ✉
We designed a protein biosensor that uses thermodynamic
coupling for sensitive and rapid detection of neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in serum. The biosensor is a
switchable, caged luciferase–receptor-binding domain (RBD)
construct that detects serum-antibody interference with the
binding of virus RBD to angiotensin-converting enzyme 2
(ACE-2) as a proxy for neutralization. Our coupling approach
does not require target modification and can better distinguish sample-to-sample differences in analyte binding affinity and abundance than traditional competition-based assays.
With the availability of coronavirus disease 2019 (COVID-19)
vaccines, the rise of more transmissible and pathogenic virus
mutants1 and known time-dependent declines in immunity following infection2, there is a need to determine the degree of serological
antibody protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Knowledge of individual immunity to
SARS-CoV-2 is useful not only to determine personal actions but
also to guide early therapy of patients and evaluate the efficacy of
antibody treatment and vaccines over time against emerging viral
variants of concern (VOCs)3.
The receptor-binding domain (RBD) of the SARS-CoV-2 spike
protein binds to the angiotensin-converting enzyme 2 (ACE-2)
receptor on target cells and is the immunodominant target of neutralizing antibodies (nAbs) identified from convalescent and postvaccination plasma3. Several SARS-CoV-2 VOCs have exploited
this and acquired mutations in the RBD, which allow for escape
from nAbs targeting wild-type4 (WT; Wuhan-Hu-1 SARS-CoV-2).
Serological antibody tests (ideally home-based diagnostics) are
critical to evaluate the response to vaccination and viral infection2.
Assays that measure antibody titer and neutralizing capability exist

but are not compatible with home use. Traditional affinity-based
immunoassays, such as enzyme-linked immunosorbent assays
(ELISAs)5, can quantitatively measure antibody titer, but due to
inherent complexity and instrumentation, they require a centralized laboratory for diagnostics. Antibody neutralizing capabilities
are traditionally measured in cell-based live viral infection assays
that require BSL3 facilities6. Lateral-flow antigen tests have been
introduced, but they are used primarily as binary qualitative tests
and report only binding between antibody and antigen rather than
neutralization7. Recently developed cell-free tools can measure antibody titers but cannot necessarily evaluate neutralization, and none
of the currently available tools have estimated neutralization activity against the emerging set of SARS-CoV-2 VOCs8. We aimed to
develop a sensor technology that can quantitatively measure nAb
responses against different isolates of SARS-CoV-2, be adapted
for an all-in-solution multiwell format and provide rapid results
in 1 hour, which is faster than established ELISA assays measuring
SARS-CoV-2 antibody titer (~6 hours) or cell-based neutralization
assays (~one to several days).

Design of the lucCageRBD assay

To achieve this goal, we designed an assay that focuses on antibodies competing with RBD:ACE-2 interactions as a proxy for antibody
neutralization8 (Fig. 1a,b). We adapted a designed coronavirus spike
RBD biosensor9 consisting of a switchable lucCageRBD protein
containing a ‘cage’ domain, which in the closed state of the sensor
binds a ‘latch’ domain containing the picomolar affinity RBD binding LCB1 protein10, and a lucKey protein that binds to the open state
of the sensor, reconstituting luciferase activity11. In the absence of
RBD, the sensor is in the closed state with the latch bound to the
cage, blocking luciferase reconstitution. Upon addition of RBD,
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the free energy of binding to lucCageRBD, together with that of
lucKey, drives switch opening and generation of luminescent signal
(Fig. 1b). Because the biosensor is under thermodynamic control and fully reversible, it is capable of detecting RBD-targeted
SARS-CoV-2 antibodies that compete with LCB1 at or near the
ACE-2 binding interface of RBD. Starting from the open luminescent state of the sensor bound to the RBD, addition of antibody pulls
the equilibrium toward the dark closed state (Fig. 1b).
Unlike previously described competition assays that directly
assess the extent of ACE-2:RBD complex formation (by luciferase
reconstitution or capturing of enzyme conjugated to one component) (Fig. 1d), in this thermodynamic coupling scheme, the RBD
is unmodified and free in solution. This simplifies testing reactivity
against RBD VOCs, because no labeling or further sensory protein
engineering is required. A more fundamental advantage, as illustrated by the simulations in Fig. 1e and Extended Data Fig. 1, is
that compared to ternary sensor systems that rely on direct competition of the ACE-2–RBD interaction by nAbs, our quaternary
sensor system can more readily distinguish analyte binding affinity and abundance, both of which are relevant for diagnosing the
success of vaccination. The robustness of the quaternary sensor lies
in its tunable sensitivity to detect the abundance/dissociation constant (Kd) of unknown antibodies in serum or plasma samples and
is the first step of the lucCageRBD assay setup. This step requires
pretesting different configurations or evaluating simultaneously
several configurations to determine the fraction decrease using
different dynamic ranges (as described in the decision matrix in
Fig. 1e). Distinguishing signals due to higher concentrations of
more weakly binding analytes from those due to lower concentrations of more strongly binding analytes is challenging for the simple outcompetition system, because disruption of the ACE-2:RBD
complex (and hence detection) is affected by the concentration and
affinity of the competitor to the same proportional extent. Taking
measurements for different configurations of the quaternary sensor system (changing the concentrations of the RBD and lucKey
sensor components) generates decision matrices (Fig. 1e) that better discriminate analyte concentration and affinity across a broad
range of values, including the constant [concentration]/Kd regime
that cannot be discriminated by the ternary sensor (sensor activation across the full analyte affinity and concentration ranges are
shown in Extended Data Fig. 1). Another advantage of our quaternary system is that the maximum raw sensor response in the
absence of nAb (used for signal normalization; decision matrices at
the far right in Fig. 1e) varies less between the different sensor configurations than in the ternary system, because the concentration
of the limiting component for signal generation (lucCageRBD) is
constant; variation in maximum signal is a problem for luminescent
(or other enzyme coupled) sensors because of substrate depletion
effects and instrument detection limits. This variation in maximum

signal can be reduced in the ternary system if one component is kept
fixed; however, in this case, the high-affinity/low-concentration and
low-affinity/high-concentration regimes are even harder to resolve
(Extended Data Fig. 1g,h). Substituting ACE-2 for a higher-affinity
RBD binder like LCB1 does not alleviate this problem. Finally, our
quaternary system is considerably more engineerable. The affinities
of the Latch and Key for the Cage can both be tuned to maximize
the dynamic range of the system for the relevant analyte affinities and concentrations, whereas to tune response in the ternary
system, only mutations at the interface between the interacting
partners can be made, which may be insufficient to obtain the
desired detection range.

LucCageRBD assay estimates neutralization potency of
mAbs

To characterize the quaternary sensor system experimentally, we
investigated the modulation of lucCageRBD signal by combinations
of RBD (and RBD variants) and RBD binding proteins. Addition
of 333 pM RBD to the sensor resulted in a rapid (t1/2 = 22 min)
fivefold increase in luminescence from baseline, which was rapidly quenched (t1/2 = 10 min) by subsequent addition of 200 nM
LCB1, which competitively inhibits RBD binding to the RBD sensor (Extended Data Fig. 2). LucCageRBD also detects Alpha, Beta
and Delta RBDs (Extended Data Fig. 3) and the interaction of these
proteins with nAbs, such as the Delta-nAb SPD-M162 (Fig. 1f), a
validated anti-SARS-CoV-2 spike RBD IgM. To quantify the extent
of binding of a competitor antibody or other RBD binding protein,
we used as a metric the fraction decrease in total sensor dynamic
range (Fig. 1b; this is also used in the simulations above). As predicted by the model, half-maximal effective concentration (EC50)
values for lucCageRBD detection of the neutralizing mAb CV30
(ref. 12) increase with increasing RBD concentration and decrease
with increasing sensor concentration (maintaining 1:1 stoichiometry with RBD) (Extended Data Fig. 4), illustrating how changing RBD and sensor concentrations can tune the sensitivity of the
lucCageRBD assay.
To evaluate the detection of nAbs through equilibrium perturbation of the lucCageRBD:RBD system, we compared binding to
the spike, virus neutralization (live virus for Fig. 1i,l, pseudovirus
for Fig. 1o and Extended Data Fig. 5c,f), and sensor activation
over a set of five anti-spike mAbs (SARS2-02, SARS2-38, CV30,
B38 and CR3022)13–16 for the WT, Alpha, and Beta spike variants
(Fig. 1g–o and Extended Data Fig. 5), one of which (CR3022) does
not interfere with ACE-2–RBD interaction15 and accordingly has
little effect in the lucCageRBD assay (Fig. 1m). Over this set of
antibodies and spike variants, virus neutralization correlates with
sensor activation better than with spike binding affinity (Extended
Data Fig. 5g–i), as expected, because the sensor is only sensitive to
binding near the ACE-2 binding site which is the target of most

Fig. 1 | Design and characterization of sensors for mAb detection. a, To detect nAbs that primarily block the interaction between ACE-2 and the RBD
of SARS-CoV-2 spike WT and other emerging variants, we designed our lucCageRBD assay, which uses the RBD sensor and lucKey. b–d, Schematic
and workflow of the LOCKR nAb biosensor system (quaternary, this work) (b and c) and ACE-2:RBD outcompetition format (ternary, previous work)
(d). The RBD sensor contains two domains that interact, the Cage and Latch, the latter of which contains small NanoLuc binary technology (smBiT) of
luciferase (blue) and the de novo LCB1 domain (yellow) designed to recognize the ACE-2 binding region of RBD. lucKey contains the Cage-associating
key domain and large NanoLuc binary technology (lgBiT) of luciferase (blue). RBD WT or variants bind to LCB1, which together with Key–Cage binding
enables reconstitution of luciferase, thus increasing luminescence. nAbs compete for RBD binding, thus shifting for Cage–Latch binding, limiting Key–
Cage interaction and disturbing luciferase reconstitution, thus decreasing luminescence. As increasing nAb concentrations should promote decreases
in luminescence, we created the fraction of lucCageRBD dynamic range lost metric. e, Simulations for the detection and deconvolution of nAb titer from
affinity. Each sub-plot represents the sensor’s responses across the different settings of the decision matrix, which is defined by a combination of lucKey
and RBD concentrations (quaternary system; left) or ACE-2 and RBD concentrations (ternary system; right). For each sensor system, the raw maximum
signal (absence of nAb, used for signal normalization) is also shown (blue heat maps). f–o, Different concentrations of SPD-M162 (f), SARS2-02 (g–i),
SARS2-38 (j–l) or CR3022 (m–o) mAbs with 5 nM RBD WT, Alpha, Beta or Delta were tested in the lucCageRBD assay (f,g,j and m), BLI for binding to
RBD isolates (h,k and n) and spike VOC-containing SARS-CoV-2 live virus (i and l) or vesicular stomatitis virus (VSV)-based pseudovirus infection (o).
The lucCageRBD and BLI experiments were performed in triplicate, viral infection experiments were performed in duplicate and data are mean ± s.e.m.
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Fig. 2 | Detection of nAbs in clinical samples. a–d, Serum from convalescent or vaccinated patients (positive samples, n = 40 for WT, n = 36 for Delta) and
pre-2019 samples (negative samples, n = 24 for both WT and Delta) were collected and tested in the lucCageRBD assay at the indicated dilutions (a and c)
and pseudovirus infection (b and d) against both WT and Delta RBD/spike. a, Associated sensitivity, specificity, positive predictive value and negative
predictive value statistics are in Supplementary Table 2 and were calculated with 3 s.d. above negative sample mean (dotted line in a and c) as the predictive
cutoff. b, 2% dilution, R2 = 0.686, Pearson’s r = 0.828; 0.4% dilution, R2 = 0.522, Pearson’s r = 0.722. d, 10% dilution, R2=0.807, Pearson’s r = 0.898;
2% dilution, R2 = 0.755, Pearson’s r = 0.869, ****P < 0.0001, two-tailed Student’s t test. a, 2% dilution, ****P = 3.84 × 10−38; 0.4% dilution, 5.5 × 10−23.
c, 10% dilution, ****P = 4.28 × 10−17; 2% dilution, ****P = 3.21 × 10−12. Viral infection experiments were performed in duplicate and data are mean ± s.e.m.

nAbs. As an example, the SARS2-02 antibody binds (by biolayer
interferometry (BLI)) Beta and WT RBD (Fig. 1h) with roughly
equal affinities, but neutralizes infectious SARS-CoV-2 (live virus)
containing WT and Alpha spike proteins much more potently
(20- to 40-fold increase in half-maximum inhibitory concentration
(IC50)) than Beta spike-containing virus13 (Fig. 1i). Consistent with
the neutralization results, the SARS2-02 antibody produces a large
decrease in lucCageRBD signal with WT and Alpha RBD but a partial response with Beta RBD (EC50 ~40-fold increased) (Fig. 1g and
Supplementary Table 1). To confirm the ability to differentiate nAb
concentration and affinity suggested by the simulations in Fig. 1e,
we assayed two antibodies (CV30 and B38) with different affinities
for WT RBD at two different concentrations each, using four different sensor settings, and found that the differential sensor readings
for each condition were consistent with the computational model
(Extended Data Fig. 1i,j).

LucCageRBD assay robustly detects nAbs in complex
samples, including clinical samples

We next investigated whether the correlation between sensor response and neutralizing activity observed over the panel of
monoclonal antibodies (mAbs) held for polyclonal antibodies in

serum. As complex biological matrices can affect absolute luminescent readings, we used Antares2 as a BRET reference for internal
calibration, and used as a measure of sensor activation the ratio of
luminescence signal to the internal standard11 (Methods). Before
vaccination, mouse serum samples17 did not decrease activation,
whereas serum samples after prime dosing (week 3) and after boost
dosing (week 5) showed progressively larger decreases in activation. Decreases in the luminescence ratio correlate (R2 = 0.711)
with the log10 IC50 values against WT spike-presenting pseudovirus
(Extended Data Fig. 6a) and the log10 reciprocal EC50 titer measured
in ELISA (R2 = 0.917) (Extended Data Fig. 6b). In serum samples
from humans vaccinated with BNT162b2 against WT, Alpha and
Beta RBD, the lucCageRBD loss in dynamic range correlates with
the SARS-CoV-2 (WT) antibody titer detected from ELISA using
the log10 of the Z-score metric (Extended Data Fig. 6d) (R2 = 0.942)
and with log10 IC50 values against pseudovirus displaying either WT
(R2 = 0.832), Alpha (R2 = 0.89) or Beta spike (R2 = 0.961) proteins
(Extended Data Fig. 6c). We next evaluated lucCageRBD responses
over 40 samples containing SARS-CoV-2 nAbs from persons convalescent, vaccinated or both with a broad range of titers and 24 pre2019 samples against different SARS-CoV-2 VOCs and dilutions
(Fig. 2 and Supplementary Table 2). For both WT and Delta RBD,
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the lucCageRBD assay positively correlates with the SARS-CoV-2
antibody titer detected from cell-based pseudovirus neutralization experiments (Fig. 2b,d and Extended Data Fig. 7) and ELISA
(Extended Data Fig. 8), and the discrimination between pre- and
post-COVID exposure was nearly perfect for both WT and Delta
versions of the sensor (Fig. 2a,c), with weaker potency generally
observed against Delta. These results suggest that our assay can
serve as a proxy for a much more involved virus neutralization assay
against WT and VOC viruses.

Discussion

Our sensor complements previously described COVID-19 serological tests. First, our sensor does not require labeling of the RBD or
variant RBDs, which makes it straightforward to substitute in new
escape variant RBDs as they are identified. Previous studies have
demonstrated detection of antibodies against the WT RBD; here,
we demonstrate differentiation between antibodies based on their
extent of reaction with WT and escape variant RBDs. Second, the
components of the sensor can be readily made in Escherichia coli
and can be lyophilized without loss of performance (Extended Data
Figs. 9 and 10); hence, there are potential advantages in shelf life and
manufacturing. The low stability of the ACE-2 protein has complicated high throughput, one-step serological detection of nAbs18, and
use of the hyperstable LCB1 instead avoids this problem. A potential
limitation of the lucCageRBD assay is that it detects only antibodies
which bind at the ACE-2 binding site of the RBD and hence cannot
quantify antibodies binding to other regions of spike or nucleocapsid19, but the RBD is a dominant target of nAbs, and hence, as confirmed by the strong correlation with neutralization titer over the
human samples, this is not a substantial limitation. Further research
will focus on incorporating the sensor into a scalable 384-well
high-throughput format or a low-cost point-of-care diagnostic testing platform. More generally, with the recent advances of computational design to generate high-affinity binding proteins and protein
switches, the approach described in this paper should be readily
extensible to quantification of the binding affinity and abundance
of a wide variety of analytes of interest.
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Methods

Cells. HEK293T/17 is a human embryonic kidney cell line (ATCC, CRL-11268).
The HEK-ACE-2 adherent cell line was obtained through BEI Resources
(NR-52511). All adherent cells were cultured at 37 °C with 8% CO2 in flasks with
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) (Hyclone) and 1% penicillin-streptomycin (PenStrep).
HEK293F is a female human embryonic kidney cell line transformed and
adapted to grow in suspension (Life Technologies). HEK293F cells were grown
in 293FreeStyle expression medium (Life Technologies), cultured at 37 °C
with 8% CO2 and shaking at 130 rpm. Expi293F cells are derived from the
HEK293F cell line (Life Technologies). Expi293F cells were grown in Expi293
Expression Medium (Life Technologies), cultured at 36.5 °C with 8% CO2
and shaking at 150 rpm.
Vero E6 (CRL-1586, American Type Culture Collection), Vero-TMPRSS2
(a gift of S. Ding, Washington University) and Vero-hACE2-TMPRSS2
(a gift of A. Creanga and B. Graham, National Institutes of Health (NIH)) cells
were cultured at 37 °C in DMEM supplemented with 10% FBS, 10 mM HEPES
(pH 7.3), 1 mM sodium pyruvate, 1× nonessential amino acids and 100 U ml−1
PenStrep. Vero-TMPRSS2 cell cultures were supplemented with 5 μg ml−1
blasticidin. TMPRSS2 expression was confirmed using an anti-V5 antibody
(Thermo Fisher Scientific, 2F11F7) or anti-TMPRSS2 mAb (Abnova,
Clone 2F4) and APC-conjugated goat anti-mouse IgG (BioLegend, 405308).
Vero-hACE2-TMPRSS2 cell cultures were supplemented with 10 μg ml−1
puromycin.
mAbs. The murine mAbs SARS2-02 and SARS2-38 studied were isolated from
BALB/c mice immunized with SARS-CoV-2 spike and RBD proteins and have
been described previously17. Genes encoding CR3022, B38 and CV30 heavy and
light chains were ordered from GenScript and cloned into pCMV/R. Antibodies
were expressed by transient cotransfection of both heavy- and light-chain
plasmids in Expi293F cells using PEI-MAX (Polyscience) transfection reagent.
Cell supernatants were harvested and clarified after 3 or 6 days, and protein was
purified using protein A chromatography (Cytiva). SPD-M162 was obtained from
AcroBiosystems (AM122).
Live virus production. The 2019n-CoV/USA_WA1/2020 isolate of SARS-CoV-2
was obtained from the US Centers for Disease Control. The Alpha isolate
was obtained from a nasopharyngeal sample after propagation on Vero-hACE2TMPRSS2 cells3. The chimeric WA1/2020 displaying Beta virus has been described
previously3. All viruses were deep-sequenced and tittered on Vero-TMPRSS2 cells,
and experiments were performed in an approved biosafety level 3 facility.
Pseudovirus production. Murine leukemia virus (MLV)-based and human
immunodeficiency virus (HIV) SARS-CoV-2 S pseudotypes were prepared as
previously described20,21. Briefly for MLV, HEK293T cells were cotransfected using
Lipofectamine 2000 (Life Technologies) with an S-encoding plasmid, an MLV
Gag–Pol packaging construct and the MLV transfer vector encoding a luciferase
reporter according to the manufacturer’s instructions. For HIV, HEK293T cells
were cotransfected using Lipofectamine 2000 (Life Technologies) with an
S-encoding plasmid, an HIV Gag-Pol, Tat, Rev1B packaging construct and the
HIV transfer vector encoding a luciferase reporter according to the manufacturer’s
instructions. Cells were washed three times with Opti-MEM before transfection
and incubated for ~5 h at 37 °C with transfection medium. DMEM containing 10%
FBS was added for ~60 h. The supernatants were harvested by spinning at 2,500 g,
filtered through a 0.45-mm filter, concentrated with a 100-kDa membrane for
10 min at 2,500 g and then aliquoted and stored at −80 °C before use.
D614G SARS-CoV-2 S (YP 009724390.1), Alpha S, Beta S and Delta S
pseudotypes VSVs were prepared as described previously22. Briefly, 293T cells in
DMEM supplemented with 10% FBS, 1% PenStrep seeded in 10-cm dishes were
transfected with the plasmid encoding for the corresponding S glycoprotein using
Lipofectamine 2000 (Life Technologies) following the manufacturer’s indications.
One day after transfection, cells were infected with VSV(G*ΔG-luciferase)
and after 2 h were washed five times with DMEM before adding medium
supplemented with anti-VSV-G antibody (ATCC, I1- mouse hybridoma
supernatant, CRL- 2700). Virus pseudotypes were harvested 18–24 h after
inoculation, clarified by centrifugation at 2,500 g for 5 min, filtered through
a 0.45-μm cutoff membrane, concentrated 10 times with a 30-kDa cutoff
membrane, aliquoted and stored at −80 °C.
Mouse serum. Female BALB/c (stock 000651) mice were purchased at the age
of 4 weeks from The Jackson Laboratory and maintained at the Comparative
Medicine Facility at the University of Washington (Seattle, WA), accredited by
the American Association for the Accreditation of Laboratory Animal Care
International. At 6 weeks of age, mice were immunized, and 3 weeks later,
animals were boosted. Before inoculation, immunogen suspensions were
gently mixed 1:1 vol/vol with AddaVax adjuvant (Invivogen) to reach a final
concentration of 0.009 or 0.05 mg ml−1 antigen. Mice were injected intramuscularly
into the gastrocnemius muscle of each hind leg using a 27-G needle (BD) with
50 ml per injection site (100 ml total) of immunogen under isoflurane anesthesia.
Nature Biotechnology | www.nature.com/naturebiotechnology
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To obtain sera, all mice were bled 2 weeks after prime and boost immunizations.
Blood was collected via submental venous puncture and rested in 1.5-ml plastic
Eppendorf tubes at room temperature for 30 min to allow for coagulation.
Serum was separated from hematocrit via centrifugation at 2,000 g for 10 min.
Complement factors and pathogens in isolated serum were heat-inactivated via
incubation at 56 °C for 60 min. Serum was stored at 4 °C or −80 °C until use.
Mouse sera in this study were used in a previous study17.
Human serum and ELISA. Immune human sera/plasma specimens were from
persons with documented SARS-CoV-2 infection in the United States between
February and August 2020. Samples were obtained before vaccination or after
vaccination with BNT162b2 or M1273 mRNA, after obtaining informed written
consent in an institutional review board-approved protocol23. Antibodies to the
SARS-CoV-2 spike protein were measured using an ELISA specific for anti-S1
IgG (Euroimmun). Antibody levels were quantified by conversion of the optical
density to a z-score relative to prepandemic serum anti-S1 IgG concentrations,
as previously described23. Sera tests were serial specimens obtained following
immunization of laboratory volunteers in an institutional review board-compliant
protocol. The negative samples (no SARS-CoV-2 nAbs) were serum samples
collected for VZV research in 2016 and 2017, before SARS-CoV-2 was spreading
in the United States.
General procedures for bacterial protein production and purification. The
E. coli Lemo21(DE3) strain (New England Biolabs) was transformed with a
pET29b+ plasmid encoding the synthesized gene of interest. Cells were grown
for 24 h in LB medium supplemented with kanamycin. Cells were inoculated at a
1:50 ml ratio in the Studier TBM-5052 autoinduction medium supplemented
with kanamycin, grown at 37 °C for 2–4 h and then grown at 18 °C for an additional
18 h. Cells were collected by centrifugation at 4,000 g at 4 °C for 15 min and
resuspended in 30 ml lysis buffer (20 mM Tris-HCl, pH 8.0, 300 mM NaCl,
30 mM imidazole, 1 mM PMSF and 0.02 mg ml−1 DNase). Cell resuspensions were
lysed by sonication for 2.5 min (5 s cycles). Lysates were clarified by centrifugation
at 24,000 g at 4 °C for 20 min and passed through 2-ml Ni-NTA nickel resin
(Qiagen, 30250) pre-equilibrated with wash buffer (20 mM Tris-HCl, pH 8.0,
300 mM NaCl and 30 mM imidazole). The resin was washed twice with 10 column
volumes (CVs) of wash buffer, and then eluted with 3 CVs elution buffer (20 mM
Tris-HCl, pH 8.0, 300 mM NaCl and 300 mM imidazole). The eluted proteins
were concentrated using Ultra-15 Centrifugal Filter Units (Amicon) and further
purified by using a Superdex 75 Increase 10/300 GL (GE Healthcare) size
exclusion column in TBS (25 mM Tris-HCl, pH 8.0, and 150 mM NaCl). Fractions
containing monomeric protein were pooled, concentrated and snap-frozen in
liquid nitrogen and stored at −80 °C.
Plasmid construction for RBD. The SARS-CoV-2 RBD (UniProt: P0DTC2) (BEI
NR-52422), Alpha (N501Y), Beta (K417N, E484K and N501Y) and Delta (L452R
and T478K) constructs were synthesized by GenScript into pcDNA3.1- or CMVR
with an N-terminal mu-phosphatase signal peptide and a C-terminal octa-histidine
tag (GHHHHHHHH). The boundaries of the construct are N-328RFPN331 and
528KKST531-C (ref. 17).
Transient transfection. RBD proteins were produced in Expi293F cells grown
in suspension using Expi293F expression medium (Life Technologies) at 33 °C,
70% humidity, 8% CO2 rotating at 150 rpm. The cultures were transfected using
PEI-MAX (Polyscience) with cells grown to a density of 3.0 million cells per
milliliter and cultivated for 3 days. Supernatants were clarified by centrifugation
(5 min at 4,000 rcf), addition of polydiallyldimethylammonium chloride solution
to a final concentration of 0.0375% (Sigma Aldrich, 409014) and a second spin
(5 min at 4,000 rcf).
Purification of RBD. His-tagged RBD was purified from clarified supernatants
via a batch bind method, where each clarified supernatant was supplemented
with 1 M Tris-HCl, pH 8.0, to a final concentration of 45 mM and 5 M NaCl to
a final concentration of 310 mM. Talon cobalt affinity resin (Takara Bio) was
added to the treated supernatants and allowed to incubate for 15 min with gentle
shaking. Resin was collected using vacuum filtration with a 0.2-mm filter and
transferred to a gravity column. The resin was washed with 20 mM Tris, pH 8.0,
300 mM NaCl, and the protein was eluted with 3 CVs of 20 mM Tris, pH 8.0,
300 mM NaCl and 300 mM imidazole. The batch bind process was then repeated
and the first and second elutions combined. SDS-PAGE was used to assess purity.
Following immobilized metal affinity chromatography purification, the elution
was concentrated and applied to a Cytiva S200 Increase column equilibrated with
20 mM Tris 150 mM NaCl, pH 8.0, and the peak of interest was collected and
quantified using A280. The purified RBD was qualified using BLI to confirm
binding using CR3022 and hACE2-Fc.
In vitro bioluminescence characterization with mAbs. A Synergy Neo2
Microplate Reader (BioTek) was used for all in vitro bioluminescence
measurements. Assays were performed in 50% HBS-EP (GE Healthcare Life
Sciences) plus 50% Nano-Glo assay buffer. For each well of a white opaque 96-well
plate, 5 μl of 10× lucCage, 5 μl of 10× lucKey, 5 μl of 10× RBD and 5 μl of 10×
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antibody and remaining volume of buffer for in total 50 μl were mixed to reach
the indicated concentration and ratio. The lucCage and lucKey components were
incubated for 30 min at room temperature to enable pre-equilibration. The plate
was centrifuged at 1,000 g for 10 s and incubated at room temperature for a further
30 min. Then, 15 μl of 100× diluted furimazine (Promega, Nano-Glo luciferase
assay reagent) was added to each well. Bioluminescence measurements in the
absence of target were taken every 1 min (0.1 s integration and 10 s shaking during
intervals) for a total of 30 min. To calculate the percent decrease in dynamic range
for the graphs, the following formula was used:
Fraction of lucCageRBD dynamic range lost = 1 −

Lx − Lmin
,
Lmax − Lmin

where Lx is the luminosity with 5 nM RBD and the tested antibody concentration,
Lmin is the luminosity when no RBD is added, and Lmax is the luminosity when only
5 nM RBD is added. To derive EC50 values from the bioluminescence-to-analyte plot,
the top three peak bioluminescence intensities at individual analyte concentrations
were averaged, subtracted from blank and used to fit the sigmoidal 4PL curve.
Detection of spiked RBD in human serum specimens. Serum specimens were
derived from excess plasma or sera from adults (>18 years) of both genders
provided by the Director of the Clinical Chemistry Division, the hospital
of University Washington. Serum specimens were obtained in compliance
with approval by the University of Washington Human Subjects Division. All
anonymized donor specimens were provided deidentified. Because the donors
consented to have their excess specimens be used for other experimental studies,
they could be transferred to our study without additional consent. All samples
were passed through 0.22-μm filters before use, and 5 μl of 10× monomeric RBD
(10 or 1,000 nM), 5 μl of 10× lucCage (10 nM), 5 μl of 10× lucKey (10 nM), 5 μl
of 10× Antares2 (0.5 nM) and the indicated amount of human donor serum or
simulated nasal matrix were mixed with 1:1 HBS/Nano-Glo assay buffer to reach
a total volume of 50 μl. The plate was centrifuged at 1,000 g for 10 s. After 30-min
incubation, 15 μl of 100× diluted furimazine in buffer was added to each well.
Bioluminescence signals were recorded from both 470/40-nm and 590/35-nm
channels every 1 min for a total of 30 min. The ratio (R) at each time point was
calculated by the following equation as previously described11:
R=

T470 nm − T590 nm × 0.43
,
T590 nm

where T470 nm and T590 nm are the total luminescent signals at 470 nm and 590 nm,
respectively. For calculating the fraction of lucCageRBD dynamic range lost for
serum samples in Extended Data Fig. 6, the following equation was used:
Fraction of lucCageRBD dynamic range lost = 1 −

Rx − Rmin
,
Rmax − Rmin

where Rx is the R with 1 nM RBD in serum sample, Rmin is the R of serum sample
but no RBD, and Rmax is the R of 100 nM RBD in the same serum sample.
To assay 64 serum samples in Fig. 2 and Extended Data Fig. 8 (including
40 from either convalescent or vaccinated patients and 24 pre-2019 donors),
5 μl proper diluted serum sample and 5 μl of 10 nM RBD (WT or Delta) were
premixed in DPBS for 20 min at room temperature. A 15-μl mixture containing
5 μl lucCageRBD (10 nM), 5 μl lucKey (10 nM) and 5 μl Antares2 (0.2 nM)
was subsequently added to each well and incubated for another 10 min; 25 μl
furimazine substrate (200× dilution) was added to each well, and luminescence
signals were acquired immediately by Neo2 plate reader at 470/40-nm and
590/35-nm channels for a total of 20 min (1-min interval and 0.1-s exposure, and
instrumental gain values were set to 120 at the 470-nm channel and 145 at the
590-nm channel). The final assay concentration contains 1 nM lucCageRBD, 1 nM
lucKey, 20 pM Antares2 and 1 nM RBD. The person performing the lucCageRBD
assays was blinded as to the serum samples being tested, and another person
analyzed the assay data. For calculating the fraction of lucCageRBD dynamic range
lost for serum samples in Fig. 2 and Extended Data Fig. 8, the following equation
was used:
Fractional decrease in lucCageRBD signal = 1 −

Rx − Rmin
.
Rmin

To simplify the calculation, Rx here is reported as the ratio of the total
luminescent signal at 470 nm over 590 nm (T470 nm/T590 nm) with 1 nM RBD in serum
sample and Rmin is the ratio of serum sample without the addition of RBD. Ten
steady-state ratio values were averaged and assigned as Rx of the corresponding
sample. Rmax was omitted herein because Rmax was unreliable with some samples
due to high nAb titer.
In vitro bioluminescence characterization of lyophilized biosensors. Five
microliters of 10× lucCage and 5 μl of 10× lucKey were added to each well of
a white opaque 96-well plate and lyophilized overnight. The biosensor was
reconstituted in 10 μl dH20 before testing, and then 84 μl of 50% HBS-EP (GE
Healthcare Life Sciences) plus 50% Nano-Glo assay buffer was added to each
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well. The lucCage and lucKey components were incubated for 30 min at room
temperature to enable pre-equilibration. One microliter of 100× diluted furimazine
was added to each well. The plate was centrifuged at 1,000 g for 10 s. Then, 5 μl
serially diluted target RBD was added to each well and measured in a A Synergy
Neo2 Microplate Reader. Measurements were taken every 1 min (0.1-s integration
and 10-s shaking during intervals) for a total of 90 min.
BLI. Protein–protein interactions were measured by using an Octet RED96 System
(ForteBio) using streptavidin-coated biosensors (ForteBio). Each well contained
200 μl solution, and the assay buffer was HBS-EP + buffer (GE Healthcare Life
Sciences, 10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% (v/v)
surfactant P20) plus 0.5% non-fat dry milk blotting grade blocker (Bio-Rad).
The biosensor tips were loaded with analyte peptide or protein at 20 μg ml−1 for
300 s (threshold of 0.8-nm response), incubated in HBS-EP + buffer for 60 s to
acquire the baseline measurement, dipped into the solution containing cage
and/or key for 1,800 s (association step) and dipped into the HBS-EP + buffer
for 1,800 s (dissociation steps). The binding data were analyzed with the ForteBio
Data Analysis Software version 9.0.0.10.
Live and pseudovirus entry and serum neutralization assays. SARS2-02
and SARS2-38 were assayed for neutralization potency by focus-reduction
neutralization test as described previously24 and using Vero-TMPRSS2 cells.
Briefly, serial dilutions of antibody were incubated with 2 × 102 focus-forming
units of SARS-CoV-2 of the indicated strain for 1 h at 37 °C in duplicate. Immune
complexes were then added to Vero-TMRPSS2 cell monolayers in a 96-well plate
and incubated for 1 h at 37 °C before the addition of 1% (w/v) methylcellulose
in MEM. Following incubation for 30 h at 37 °C, cells were fixed with 4%
paraformaldehyde, permeabilized and stained for infection foci with a mixture of
mAbs that bind various epitopes on the RBD and NTD of spike (SARS2-02 and
SARS2-38; diluted to 1 µg ml−1 total mAb concentration). Antibody–dose response
curves were analyzed using nonlinear regression analysis (with a variable slope)
(GraphPad Software).
For the mAbs CV30, B38 and CR3022 and for the vaccinated human
serum samples with pseudovirus, HEK-hACE2 cells were cultured in DMEM
with 10% FBS (Hyclone) and 1% PenStrep with 8% CO2 in a 37 °C incubator
(Thermo Fisher Scientific). Before plating, 40 µl poly-lysine (Sigma) was
placed into 96-well plates and incubated with rotation for 5 min. Poly-lysine
was removed, plates were dried for 5 min then washed 1× with water before
plating 2 × 104 cells. The following day, cells were checked to be at 80% confluence.
In a half-area 96-well plate a 1:3 serial dilution of mAb or sera was made in
DMEM in 22 µl final volume. 22 µl pseudovirus was then added to the serial
dilution and incubated at room temperature for 30–60 min. HEK-hACE2
plate media was removed and 40 µl of the sera/virus mixture was added to
the cells and incubated for 2 h at 37 °C with 8% CO2. Following incubation,
40 µl 20% FBS and 2% PenStrep containing DMEM was added to the cells for
24–48 h. Following the infection, One-Glo-EX (Promega) was added to the
cells in half culturing volume (40 µl added) and incubated in the dark for 5 min
before reading on a BioTek plate reader. Measurements were done on all
mAbs and human serum samples from each group in at least duplicate. Relative
luciferase units were plotted and normalized in Prism (GraphPad) using a zero
value of cells alone and a 100% value of 1:2 virus alone. Nonlinear regression
of log(inhibitor) versus normalized response was used to determine IC50 values
from curve fits.
Sensor simulations. Mathematical models describing the ternary and quaternary
sensor systems were simulated to test their responses to changes in their input
parameters (concentrations and affinities of intervening species). Systems of
ordinary differential equations describing the kinetics of the interactions between
the species involved in each sensor were numerically integrated using integrate.
odeint() as implemented in Scipy (version 1.6.3) (ref. 25). Steady-state values were
used to determine the distribution of species at thermodynamic equilibrium.
The ternary system is composed of the following species: ACE-2, RBD,
nAb, ACE-2:RBD and RBD:nAb. The following set of equations was used to
describe the system:
d [ACE2]
= −k1 [ACE2] [RBD] + k−1 [ACE2 : RBD]
dt
d [RBD]
= −k1 [ACE2] [RBD] + k−1 [ACE2 : RBD]
dt
−k2 [RBD] [nAb] + k−2 [RBD : nAb]

d [nAb]
= −k2 [RBD] [nAb] + k−2 [RBD : nAb]
dt
d [ACE2 : RBD]
= k1 [ACE2] [RBD] − k−1 [ACE2 : RBD]
dt
d [RBD : nAb]
= k2 [RBD] [nAb] − k−2 [RBD : nAb] ,
dt
Nature Biotechnology | www.nature.com/naturebiotechnology
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where ki describe bimolecular association rate constants and k-i represent
unimolecular dissociation rate constants. K1 = k−1/k1 and K2 = k−2/k2 describe the
equilibrium dissociation constants for the ACE-2:RBD and RBD:nAb complexes,
respectively. For all ternary system simulations, K1 was set to 15 nM (ref. 26). For
consistency with the metric used to report on the quaternary system response
(fraction of lucCageRBD dynamic range lost; described in section ‘In vitro
bioluminescence characterization with monoclonal antibodies’), simulations for
the ternary system were reported as:
Fraction sensor dynamic range lost = 1 − Lx /Lmax ,

where Lx is the signal observed when all three species are present, and Lmax is the
response when nAb is absent.
The quaternary system is composed of the following species: closed state of the
Cage-Latch, open state of the Cage-Latch (oCL), lucKey, RBD, nAb, lucKey:oCL,
oCL:RBD, lucKey:oCL:RBD and RBD:nAb. Only the oCL is considered
binding-competent, whereas the closed state of the Cage-Latch is not. The
following set of equations was used to describe the system:
d [cCL]
= −k [cCL] + k− [oCL]
dt
d [oCL]
= k [cCL] − k− [oCL] − k1 [lucKey] [oCL] + k−1 [lucKey : oCL]
dt
−k2 [oCL] [RBD] + k−2 [oCL : RBD]

d [lucKey]
= −k1 [lucKey] [oCL] + k−1 [lucKey : oCL]
dt
−k1 [lucKey] [oCL : RBD] + k−1 [lucKey : oCL : RBD]

d [RBD]
= −k2 [oCL] [RBD] + k−2 [oCL : RBD] − k2 [lucKey : oCL] [RBD]
dt
+k−2 [lucKey : oCL : RBD] − k3 [RBD] [nAB] + k−3 [RBD : nAb]

d [nAb]
= −k3 [RBD] [nAB] + k−3 [RBD : nAb]
dt
d [lucKey : oCL]
= k1 [lucKey] [oCL] − k−1 [lucKey : oCL]
dt
−k2 [lucKey : oCL] [RBD] + k−2 [lucKey : oCL : RBD]

d [oCL : RBD]
= k2 [oCL] [RBD] − k−2 [oCL : RBD] − k1 [lucKey] [oCL : RBD]
dt
+k−1 [lucKey : oCL : RBD]

d [lucKey : oCL : RBD]
= k1 [lucKey] [oCL : RBD] − k−1 [lucKey : oCL : RBD]
dt
+k2 [lucKey : oCL] [RBD] − k−2 [lucKey : oCL : RBD]

d [RBD : nAb]
= k3 [RBD] [nAB] − k−3 [RBD : nAb] ,
dt

where ki describes the bimolecular association rate constant and k−i represents
the unimolecular dissociation rate constant. K1 = k−1/k1, K2 = k−2/k2 and K3 =
k−3/k3 describe the affinities (equilibrium dissociation constants) for the binding
interfaces lucKey:oCL, oCL:RBD and RBD:nAb, respectively. The binding of
lucKey and RBD to the open Cage-Latch species is considered symmetrical
(i.e., noncooperative),
( meaning) that the binding events are independent.
K = k− /k = exp ΔGopen /RT describes the unimolecular binding equilibrium
of the Latch to the Cage, with ΔGopen the free energy of Latch opening, R the
universal gas constant and T the thermodynamic temperature (set to 298.15 K for
all simulations).
These systems were simulated over a range of species concentrations, as well
as RBD:nAb affinities, to explore the behavior of each sensor, and gain insights
into the influence of different variables on the position of the detection thresholds.
The python code for running these simulations is provided as a Jupyter notebook:
https://github.com/bwicky/covid_nAb_sensor_simulation.
Statistical analysis. No statistical methods were used to predetermine the sample
size. No sample was excluded from data analysis, and no blinding was used.
Deidentified clinical serum samples were randomly used for spiking in target
proteins. Results were successfully reproduced using different batches of
pure proteins on different days. Unless otherwise indicated, data are shown
Nature Biotechnology | www.nature.com/naturebiotechnology

as mean ± s.e.m., and error bars in figures represent s.e.m. of technical triplicates.
BLI data were analyzed using ForteBio Data Analysis Software version 9.0.0.10.
All data were analyzed and plotted using GraphPad Prism 8.
Reporting Summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.

Data availability

The data that support the findings of this study are available from the
corresponding author upon reasonable request. All accession codes have been
provided for the paper. Source data are provided with this paper.

Code availability

The code for the sensor simulations is made available as an interactive Jupyter
notebook at https://github.com/bwicky/covid_nAb_sensor_simulation. Source
data are provided with this paper.
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Extended Data Fig. 1 | See next page for caption.
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Extended Data Fig. 1 | Simulation of biosensor systems and experimental validation. a, Schematic of the LOCKR nAb biosensor system (quaternary,
this work), and b, ACE-2:RBD out-competition format (ternary, previous work). These schematics are the same as in Fig. 1. c-d, Simulations of detection
capabilities as a function of sensor settings (concentration of sensor components) along the dimension of each independent variable. The decision
boundaries (EC50) are shown as solid lines. c, The concentration of RBD primarily affects the antibody titer detection limit. For tight antibodies (righthand side of the plots), the position of the decision boundary (EC50) is solely determined by the concentration of RBD. The concentrations of the
untitrated components were: Cage-Latch = 1 nM, lucKey = 50 nM for the quaternary system, and ACE-2 = 1 nM for the ternary system. d, Effect of ACE-2
or lucKey concentrations on the ternary and quaternary sensors respectively. Changing lucKey concentration in the quaternary case allows for a better
modulation of the nAb affinity detection threshold. The concentration of RBD was set to 50 nM in both cases, and the concentration of Cage-Latch was
set to 1 nM for the quaternary system. e,f, Simulations of outputs for decision matrices of the quaternary (e), orternary (f) sensors. Each matrix represents
the simulated responses for 16 different sensor settings (concentrations of sensor species, indicated at the bottom-right) to a given concentration of
nAb of a specific affinity. The quaternary system is capable of deconvoluting affinity and concentration across all combinations that activate the sensor
(distinct patterns), while the ternary system returns the same reading for the cases where nAb affinity and concentrations are in the same range (diagonal,
highlighted by dashed squares). g, Diagonal of decision matrices for ternary systems composed of RBD and LCB1 instead of ACE-2. Sensor readings using
the same concentrations of species as the ACE-2:RBD system (top) or adjusted concentrations (bottom). h, Simulated maximum raw signals for the
ternary system sensor as in (g) with unmodified settings (left), and adjusted concentrations (right). The unmodified settings reduce the raw maximum
signal range, but also reduce the detection capabilities of the sensor. Adjusting the settings to improve detection also increases the raw maximum signal
range. i-j, Comparison between simulated and experimental data. i, Different concentrations of either CV30 (high affinity; Kd = 25 nM) or B38 (low affinity;
Kd = 192 nM) mAbs with 1 nM RBD sensor and different concentrations of WT RBD and lucKey in the lucCageRBD assay (experimental and simulation
data, top and bottom respectively). j, Heat map representation summarizing some of the experimental data from (i) for low and high concentrations of
CV30 and B38 antibodies (simulation and experimental data, top and bottom respectively). All lucCageRBD experiments were performed in triplicate,
representative data are shown, and data are mean ± s.e.m. The quaternary system was simulated with the following parameters: ΔGopen = 4kcal/mol,
[Cage − Latch] = 1nM, K (lucKey : oCL) = 5nM, K (oCL : RBD) = 500pM. The ternary system was simulated with K (ACE2 : RBD) = 15nM, except
for g-h, where K (LCB1 : RBD) = 500pM was used instead. Cases where simulations did not converge are shown as white squares.
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Extended Data Fig. 2 | Reversibility of lucCageRBD. Time-course luminescence of the lucCageRBD assay using 200 nM of RBD WT and different
concentrations of the de novo LCB1.1 binder. All experiments were performed in triplicate, representative data are shown.
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Extended Data Fig. 3 | Detection of RBD strains by lucCageRBD. a–d, Fold change increase in luminescence from different concentrations of RBD WT (a),
Alpha (b), Beta (c), Delta (d) tested in the lucCageRBD assay. All experiments were performed in triplicates and data are mean ± s.e.m.
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Extended Data Fig. 4 | Effects of RBD and sensor titration on detecting SARS-CoV-2 antibodies. a,b, Resulting fraction of lucCageRBD dynamic range
lost (a) and lucCageRBD EC50 (b) from different concentrations of mAb CV30 with different concentrations of RBD WT in 1 nM of RBD sensor and
lucKey. c-d, Resulting fraction of lucCageRBD dynamic range lost (c) and lucCageRBD EC50 (d) from different concentrations of mAb CV30 with different
concentrations of RBD sensor and lucKey (1:1 stoichiometry maintained) and with 5 nM RBD. All experiments were performed in triplicates and data are
mean ± s.e.m.
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Extended Data Fig. 5 | Monoclonal antibodies tested for lucCageRBD, binding, and neutralization. a–f, Different concentrations of either CV30 (a-c)
or B38 (e-g) mAbs with 5 nM RBD WT, Alpha, and Beta were tested in the lucCageRBD assay (a, d), BLI for binding to RBD strains (b, e), and spike
VoC-presenting pseudovirus infection (VSV-based for c, HIV-based for f). Comparison of lucCageRBD EC50 and neutralization IC50 plotted linear-linear
(left) or log-log (right) (g), binding affinity (kd) and neutralization IC50 (h), and lucCageRBD EC50 and kd (i). All lucCageRBD and BLI experiments were
performed in triplicate, neutralization experiments were performed in at least duplicate and data are mean ± s.e.m.
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Extended Data Fig. 6 | Detection of neutralizing antibodies in vaccinated serum. a,b, Serum (10%) from vaccinated mice were collected and tested for
pseudovirus infection (a), in ELISA (log10 reciprocal EC50 titer) (b), and in the lucCageRBD assay (a, b) (n=12 serum samples). (Inset) Mouse serum
samples pre-immunization, post-prime dosing (week 3), and post-boost dosing (week 5) were collected and tested in the lucCageRBD assay. c-d, Serum
(10%) from vaccinated patients were tested for pseudovirus infection (c), in ELISA (log10 reciprocal EC50 titer) (d), and in the lucCageRBD assay (c, d)
using RBD WT, Alpha, and Beta (n=12 serum samples). e-f, Serum collected from patients pre and post vaccination were tested in the EuroImmun ELISA
for anti-spike antibodies. Patient’s anti-spike antibody levels (measured by Z-score) were measured several days after vaccination. Z-score is plotted either
in linear (e) or log10 scale (f). All neutralization experiments were performed in at least duplicates, all lucCageRBD and ELISA experiments were performed
in triplicate and data are mean ± s.e.m.

Nature Biotechnology | www.nature.com/naturebiotechnology

Brief Communication

NATuRE BiOTEChnOlOgy

Extended Data Fig. 7 | See next page for caption.
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Extended Data Fig. 7 | Pseudovirus neutralization curves for clinical samples. a,b, (a) Serum from convalescent and/or vaccinated patients and
pre-2019 serum samples (b) were collected and tested for pseudovirus infection against Delta spike. c, IC50 values of serum from convalescent
and/or vaccinated patients (blue) or pre-2019 serum samles (red) for blocking Delta-spike containing pseudoviral entry. Bar graph is plotted either
linearly (top) or logarithmically (bottom).
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Extended Data Fig. 8 | Detection of neutralizing antibodies in clinical samples. a, Serum from convalescent and/or vaccinated patients (positive samples,
n=40) and pre-2019 samples (negative samples, n=24) were collected and tested in both the lucCageRBD and ELISA assay and pseudovirus infection
against WT RBD. b, The same samples were tested for neutralization of either WT or Delta spike-presenting pseudovirus with log10 IC50 neutralization
reported. Viral infection experiments were performed in duplicate, and data are mean ± s.e.m. r represents pearson’s coefficient. **P=0.0012, two-tailed
student’s t-test.
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Extended Data Fig. 9 | Production and purification of recombinant proteins used in LOCKR biosensor for serological diagnosis of neutralizing
antibodies. a, Individual His6 tagged versions of lucKey (27.4 KDa) and lucCageRBD (47.8 KDa) are expressed in E. coli and following cell lysis are purified
by IMAC using 50 mM imidazole in buffer elution. b, His6 tagged SARS-CoV-2 RBD (30 KDa) is expressed as a secreted protein in human 293 cells
transiently transfected with DNA vectors encoding the protein which is purified from serum free culture medium by IMAC using 50 mM imidazole in
buffer elution. c, His6 tagged LCB1 anti-SARS-CoV-2 RBD minibinder (7 KDa) is expressed in E. coli (whole cell). Following cell lysis by heating to
95 °C and centrifugation to separate insoluble from soluble material, the LCB1 minibinder protein is >90% pure. Samples shown in A-C were analyzed
by SDS-PAGE with reducing agent and Coomassie blue staining (molecular weight standards shown). All experiments were performed in triplicate,
representative data are shown.
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Extended Data Fig. 10 | lucCageRBD biosensor sensitivity before and after lyophilization. lucCageRBD and lucKey were lyophilized at 10X concentration
in a 96-well plate. After reconstitution in liquid format, the biosensor was tested at a final concentration of 1 nM lucCageRBD and 1 nM lucKey for the
detection of serially diluted RBD. All experiments were performed in triplicates and data are mean ± s.e.m.
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